RNA Quote, Financials, Valuation and Earnings

Catalyst Pharmaceuticals has a net margin of -3439.52% compared to Avidity Biosciences's net margin of 39.44%. Avidity Biosciences's return on equity of -29.4% beat Catalyst Pharmaceuticals's return on equity of 27.81%.

Avidity Biosciences has a consensus price target of $66.69, signalling upside risk potential of 110.25%. On the other hand Catalyst Pharmaceuticals has an analysts' consensus of $33.33 which suggests that it could grow by 47.49%. Given that Avidity Biosciences has higher upside potential than Catalyst Pharmaceuticals, analysts believe Avidity Biosciences is more attractive than Catalyst Pharmaceuticals.

Avidity Biosciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Catalyst Pharmaceuticals has a beta of 0.836, suggesting its less volatile than the S&P 500 by 16.449%.

Avidity Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catalyst Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Avidity Biosciences pays -- of its earnings as a dividend. Catalyst Pharmaceuticals pays out -- of its earnings as a dividend.

Avidity Biosciences quarterly revenues are $3M, which are smaller than Catalyst Pharmaceuticals quarterly revenues of $141.8M. Avidity Biosciences's net income of -$102.3M is lower than Catalyst Pharmaceuticals's net income of $55.9M. Notably, Avidity Biosciences's price-to-earnings ratio is -- while Catalyst Pharmaceuticals's PE ratio is 17.25x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Avidity Biosciences is 324.66x versus 5.74x for Catalyst Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Ionis Pharmaceuticals has a net margin of -3439.52% compared to Avidity Biosciences's net margin of -46.06%. Avidity Biosciences's return on equity of -29.4% beat Ionis Pharmaceuticals's return on equity of -103.27%.

Avidity Biosciences has a consensus price target of $66.69, signalling upside risk potential of 110.25%. On the other hand Ionis Pharmaceuticals has an analysts' consensus of $59.50 which suggests that it could grow by 78.47%. Given that Avidity Biosciences has higher upside potential than Ionis Pharmaceuticals, analysts believe Avidity Biosciences is more attractive than Ionis Pharmaceuticals.

Avidity Biosciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Ionis Pharmaceuticals has a beta of 0.279, suggesting its less volatile than the S&P 500 by 72.122%.

Avidity Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ionis Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Avidity Biosciences pays -- of its earnings as a dividend. Ionis Pharmaceuticals pays out -- of its earnings as a dividend.

Avidity Biosciences quarterly revenues are $3M, which are smaller than Ionis Pharmaceuticals quarterly revenues of $226.6M. Avidity Biosciences's net income of -$102.3M is higher than Ionis Pharmaceuticals's net income of -$104.3M. Notably, Avidity Biosciences's price-to-earnings ratio is -- while Ionis Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Avidity Biosciences is 324.66x versus 7.07x for Ionis Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Sarepta Therapeutics has a net margin of -3439.52% compared to Avidity Biosciences's net margin of 24.16%. Avidity Biosciences's return on equity of -29.4% beat Sarepta Therapeutics's return on equity of 20.83%.

Avidity Biosciences has a consensus price target of $66.69, signalling upside risk potential of 110.25%. On the other hand Sarepta Therapeutics has an analysts' consensus of $173.18 which suggests that it could grow by 116.56%. Given that Sarepta Therapeutics has higher upside potential than Avidity Biosciences, analysts believe Sarepta Therapeutics is more attractive than Avidity Biosciences.

Avidity Biosciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Sarepta Therapeutics has a beta of 0.794, suggesting its less volatile than the S&P 500 by 20.639%.

Avidity Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Avidity Biosciences pays -- of its earnings as a dividend. Sarepta Therapeutics pays out -- of its earnings as a dividend.

Avidity Biosciences quarterly revenues are $3M, which are smaller than Sarepta Therapeutics quarterly revenues of $658.4M. Avidity Biosciences's net income of -$102.3M is lower than Sarepta Therapeutics's net income of $159M. Notably, Avidity Biosciences's price-to-earnings ratio is -- while Sarepta Therapeutics's PE ratio is 35.07x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Avidity Biosciences is 324.66x versus 4.69x for Sarepta Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals has a net margin of -3439.52% compared to Avidity Biosciences's net margin of 31.35%. Avidity Biosciences's return on equity of -29.4% beat Vertex Pharmaceuticals's return on equity of -3.23%.

Avidity Biosciences has a consensus price target of $66.69, signalling upside risk potential of 110.25%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $496.78 which suggests that it could fall by -3.07%. Given that Avidity Biosciences has higher upside potential than Vertex Pharmaceuticals, analysts believe Avidity Biosciences is more attractive than Vertex Pharmaceuticals.

Avidity Biosciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.414, suggesting its less volatile than the S&P 500 by 58.629%.

Avidity Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Avidity Biosciences pays -- of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend.

Avidity Biosciences quarterly revenues are $3M, which are smaller than Vertex Pharmaceuticals quarterly revenues of $2.9B. Avidity Biosciences's net income of -$102.3M is lower than Vertex Pharmaceuticals's net income of $913M. Notably, Avidity Biosciences's price-to-earnings ratio is -- while Vertex Pharmaceuticals's PE ratio is 26.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Avidity Biosciences is 324.66x versus 12.06x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.